170 related articles for article (PubMed ID: 20803030)
1. Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma.
Ilie MI; Hofman V; Bonnetaud C; Havet K; Lespinet-Fabre V; Coëlle C; Gavric-Tanga V; Vénissac N; Mouroux J; Hofman P
Virchows Arch; 2010 Oct; 457(4):483-95. PubMed ID: 20803030
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry.
Pinter F; Papay J; Almasi A; Sapi Z; Szabo E; Kanya M; Tamasi A; Jori B; Varkondi E; Moldvay J; Szondy K; Keri G; Dominici M; Conte P; Eckhardt S; Kopper L; Schwab R; Petak I
J Mol Diagn; 2008 Mar; 10(2):160-8. PubMed ID: 18258923
[TBL] [Abstract][Full Text] [Related]
3. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma.
Wen YH; Brogi E; Hasanovic A; Ladanyi M; Soslow RA; Chitale D; Shia J; Moreira AL
Mod Pathol; 2013 Sep; 26(9):1197-203. PubMed ID: 23599147
[TBL] [Abstract][Full Text] [Related]
5. Identification of EGFR Mutations by Immunohistochemistry with EGFR Mutation-Specific Antibodies in Biopsy and Resection Specimens from Pulmonary Adenocarcinoma.
Kim CH; Kim SH; Park SY; Yoo J; Kim SK; Kim HK
Cancer Res Treat; 2015 Oct; 47(4):653-60. PubMed ID: 25687872
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression.
Dziadziuszko R; Merrick DT; Witta SE; Mendoza AD; Szostakiewicz B; Szymanowska A; Rzyman W; Dziadziuszko K; Jassem J; Bunn PA; Varella-Garcia M; Hirsch FR
J Clin Oncol; 2010 May; 28(13):2174-80. PubMed ID: 20351332
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: the need to test neoplasms with more than one method.
Gupta R; Dastane AM; Forozan F; Riley-Portuguez A; Chung F; Lopategui J; Marchevsky AM
Mod Pathol; 2009 Jan; 22(1):128-33. PubMed ID: 18997733
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral distribution of EGFR-amplified and EGFR-mutated cells in pulmonary adenocarcinoma.
Soma S; Tsuta K; Takano T; Hatanaka Y; Yoshida A; Suzuki K; Asamura H; Tsuda H
Pathol Res Pract; 2014 Mar; 210(3):155-60. PubMed ID: 24355440
[TBL] [Abstract][Full Text] [Related]
9. Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples.
Fan X; Liu B; Xu H; Yu B; Shi S; Zhang J; Wang X; Wang J; Lu Z; Ma H; Zhou X
Hum Pathol; 2013 Aug; 44(8):1499-507. PubMed ID: 23465272
[TBL] [Abstract][Full Text] [Related]
10. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.
Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Uehara T; Fujimoto M; Tsuruyama T; Date H; Haga H
Lung Cancer; 2014 Sep; 85(3):373-8. PubMed ID: 25047676
[TBL] [Abstract][Full Text] [Related]
11. Chromogenic in situ hybridization to detect EGFR gene copy number in cell blocks from fine-needle aspirates of non small cell lung carcinomas and lung metastases from colo-rectal cancer.
Simone G; Mangia A; Malfettone A; Rubini V; Siciliano M; Di Benedetto A; Terrenato I; Novelli F; Mottolese M
J Exp Clin Cancer Res; 2010 Sep; 29(1):125. PubMed ID: 20843314
[TBL] [Abstract][Full Text] [Related]
12. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.
Kato Y; Peled N; Wynes MW; Yoshida K; Pardo M; Mascaux C; Ohira T; Tsuboi M; Matsubayashi J; Nagao T; Ikeda N; Hirsch FR
J Thorac Oncol; 2010 Oct; 5(10):1551-8. PubMed ID: 20697298
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic algorithm for detection of targetable driver mutations in lung adenocarcinomas: Comprehensive analyses of 205 cases with immunohistochemistry, real-time PCR and fluorescence in situ hybridization methods.
Kao HL; Yeh YC; Lin CH; Hsu WF; Hsieh WY; Ho HL; Chou TY
Lung Cancer; 2016 Nov; 101():40-47. PubMed ID: 27794407
[TBL] [Abstract][Full Text] [Related]
14. Comparison of FISH, PCR, and immunohistochemistry in assessing EGFR status in lung adenocarcinoma and correlation with clinicopathologic features.
El-Zammar OA; Zhang S; Katzenstein AL
Diagn Mol Pathol; 2009 Sep; 18(3):133-7. PubMed ID: 19704257
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of epidermal growth factor receptor gene status in lung adenocarcinoma.
Li C; Sun Y; Fang Z; Han X; Fang R; Zhang Y; Pan Y; Zhang W; Ren Y; Ji H; Chen H
J Thorac Oncol; 2011 Jun; 6(6):1016-21. PubMed ID: 21532505
[TBL] [Abstract][Full Text] [Related]
16. Silver-enhanced in situ hybridization for determination of EGFR copy number alterations in non-small cell lung cancer.
Wulf MA; Bode B; Zimmermann D; Rufibach K; Weder W; Moch H; Soltermann A; Tischler V
Am J Surg Pathol; 2012 Dec; 36(12):1801-8. PubMed ID: 23154768
[TBL] [Abstract][Full Text] [Related]
17. EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma.
Cooper WA; Yu B; Yip PY; Ng CC; Lum T; Farzin M; Trent RJ; Mercorella B; Clarkson A; Kohonen-Corish MR; Horvath LG; Kench JG; McCaughan B; Gill AJ; O'Toole SA
J Clin Pathol; 2013 Sep; 66(9):744-8. PubMed ID: 23757037
[TBL] [Abstract][Full Text] [Related]
18. Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC.
Gaber R; Watermann I; Kugler C; Reinmuth N; Huber RM; Schnabel PA; Vollmer E; Reck M; Goldmann T
Diagn Pathol; 2014 Sep; 9():165. PubMed ID: 25227424
[TBL] [Abstract][Full Text] [Related]
19. Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry.
Seo AN; Park TI; Jin Y; Sun PL; Kim H; Chang H; Chung JH
Lung Cancer; 2014 Mar; 83(3):316-23. PubMed ID: 24412618
[TBL] [Abstract][Full Text] [Related]
20. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.
Hirsch FR; Varella-Garcia M; Cappuzzo F; McCoy J; Bemis L; Xavier AC; Dziadziuszko R; Gumerlock P; Chansky K; West H; Gazdar AF; Crino L; Gandara DR; Franklin WA; Bunn PA
Ann Oncol; 2007 Apr; 18(4):752-60. PubMed ID: 17317677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]